Читать книгу Interventional Cardiology - Группа авторов - Страница 252

The effects of current or novel agents that modify plaque composition can be evaluated using NIRS, because it is able to assess the lipid content over time. The YELLOW trial recruited patients with multivessel CAD undergoing PCI. After NIRS and IVUS baseline assessment, patients were randomized to either rosuvastatin 40 mg/day vs the standard of care lipid‐lowering therapy. After seven weeks of short‐term intensive statin therapy, a significant reduction in the lipid content was found when measured via max LCBI_4mm [134].